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Combined Evaluation of Postoperative Serum Levels of
Carcinoembryonic Antigen Less than or Equal to 2.5 ng/ml
and Absence of Vascular Invasion may Predict no
Recurrence of Stage I Adenocarcinoma Lung Cancer
Kosuke Kashiwabara, MD, Syoh Saeki, MD, Ji-ichiro Sasaki, MD, Masanobu Nomura, MD,
and Hirotsugu Kohrogi, MD
Study Objectives: It has been reported that high levels of serum
carcinoembryonic antigen (CEA) after surgery, or the presence of
vascular invasion or both, are strong indicators of postoperative
recurrence in patients with non-small cell lung cancer. The
purpose of this study is to evaluate which kind of patients with
p-stage I adenocarcinoma need adjuvant chemotherapy, using
those predictors.
Patients and Methods: We studied 136 patients with curatively
resected p-stage I adenocarcinoma during the 7-year period of
January 1, 2000 to December 31, 2006. Receiver operating charac-
teristics curves were constructed using postoperative CEA levels
measured 2 months after surgery. Clinical variables were examined
as possible predictors of disease recurrence by multivariate analysis
using the Cox proportional-hazards model.
Results: The median time of follow-up after surgery was 28.3
months. Fifteen (11%) of 136 patients had postoperative recurrence
(7 p-stage IA cases and 8 p-stage IB cases). The presence of vascular
invasion (hazard ratio: 10.229, 95% confidence intervals: 2.811–
37.223, p  0.0004) and high postoperative CEA levels (hazard
ratio: 1.650, 95% confidence intervals: 1.196–2.275, p  0.0023)
increased the risk of recurrence. There was no recurrence in patients
who had both postoperative CEA levels less than or equal to 2.5
ng/ml and no vascular invasion.
Conclusion: Combined evaluation of postoperative CEA levels and
vascular invasion makes it possible to predict disease recurrence in
the curatively resected p-stage I adenocarcinoma patients.
Key Words: Adjuvant chemotherapy, Cox proportional-hazards
model, Predictors for postoperative recurrence, Receiver operating
characteristics (ROC) curve, Uracil/tegafur (UFT).
(J Thorac Oncol. 2008;3: 1416–1420)
According to the 2007 American College of Chest Physi-cians guidelines for diagnosis and management for lung
cancer, for both stage IA and IB non-small cell lung cancer
(NSCLC) patients who had the curative resection, adjuvant
chemotherapy has not been recommended for routine use.1 In
Japan, oral uracil/tegafur (UFT) therapy is performed as
adjuvant chemotherapy in pathologic (p-) stage IB adenocar-
cinoma patients because it has been reported that a 5-year
survival rate is 85% in the UFT group compared with 74% in
the control group (p  0.005)2 and meta-analysis has showed
that UFT therapy reduced the risk of postoperative death
(hazard ratio 0.74, 95% confidence intervals CI 0.61–0.88,
p  0.001).3 As there is as yet no way to predict beforehand
who has recurred in p-stage IB patients, UFT therapy seems
indicated for both the patients in whom the disease would not
recur even if they had not received UFT, and the patients in
whom the disease would recurred even if they had received
UFT. In addition, Tsuchiya et al.4 reported that 5-year overall
survival rate in p-stage IA NSCLC patients with pathologi-
cally vascular invasion nearly overlapped that of p-stage IB
NSCLC patients and improved significantly by postoperative
UFT therapy. It is therefore very important to accordingly
determine who needs adjuvant chemotherapy in p-stage IA
cases as well as those in whom this therapy can be avoided in
p-stage IB cases. It is now necessary to find additional
predictors for postoperative recurrence of p-stage I NSCLC
accompanied with vascular invasion.
Although there are no recommendations for the routine
measurement of any tumor markers in the screening, staging,
or evaluation of disease progression,5 many recent studies
have shown that high preoperative levels of carcinoembry-
onic antigen (CEA) in early stage adenocarcinoma of the lung
are related to poor prognosis after surgery.6–10 However, it is
also well known that serum CEA levels increase in heavy
smokers and decrease after they gave up smoking.11–13 These
results indicate that the postoperative serum CEA levels may
be a more useful prognostic predictor in lung cancer patients
because most of them give up smoking before surgery.14 It
has also been reported that in p-stage I NSCLC patients, a
high postoperative CEA level is a strong indicator of post-
operative recurrence or poor prognosis.15–17 Okada et al.18 has
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reported that normalization of CEA levels after surgery is a
significant favorable prognostic sign in patients with high
preoperative CEA levels. We sought to define the optimal
cutoff values of the postoperative CEA levels in p-stage I
adenocarcinoma patients and to identify those who would
benefit for adjuvant chemotherapy by combination of the two
conditions of postoperative CEA levels and vascular inva-
sions identified on the resected specimen.
PATIENTS AND METHODS
We enrolled 163 consecutive patients with a peripheral
tumor that was surgically given a diagnosis of p-stage I
adenocarcinoma during the 7-year period from January 1,
2000 to December 31, 2006. The indications of segmentec-
tomy or mediastinal lymph node dissection were determined
using sentinel node navigation in patients with tumors less
than 20 mm in diameter.19,20 Technetium-99m tin colloid was
injected into the peritumoral region before surgery. When an
intraoperative frozen material of sentinel nodes, identified by
measuring radioactive tracer uptake, did not pathologically
have metastasis, segmentectomy was performed and medias-
tinal lymph node dissection was omitted. Both lobectomy and
mediastinal lymph node dissection were performed in all
patients with tumors larger than 20 mm. We excluded 27
patients from this study for the following reasons: 10 patients
had an Eastern Cooperative Oncology Group performance
status 2 or 3 after surgery, 8 patients had other cancers at
surgery (2 cases with synchronous lung cancer, 2 breast
cancer, 1 colon cancer, 1 hepatic cellular carcinoma, 1 pan-
creatic cancer, and 1 thyroid cancer) and 9 cases lacked
sufficient follow-up data after surgery. A total of 136 p-stage
I adenocarcinoma patients were eligible (109 IA cases: 42
men and 67 women, 27 IB cases: 12 men and 15 women) and
staged according to the guidelines of the Union Internationale
Contre le Cancer Tumor Node Metastasis classification of ma-
lignant tumors. Informed consent was obtained from all of the
patients at the same time we explained the procedure of diag-
nostic approach.
We measured serum CEA levels within 1 month before
surgery, and 2 months, 6 months and 12 months after surgery.
Measurement of serum CEA was performed using a chemi-
luminescent immunoassay test kits (Abbott Japan Co., Ltd.,
Chiba, Japan, reference ranges 5.0 ng/ml) following the
manufacturer’s instructions. All current smokers (n  36)
gave up smoking before surgery and no one started smoking
again for at least 12 months after surgery.
We divided 136 eligible patients into 2 groups: (1)
patients who had postoperative recurrence (recurrence group)
and (2) patients without recurrence (no recurrence group).
Postoperative recurrence such as local metastasis, distant
metastasis, and chest wall implantation, was defined as the
first appearance of any new lesion suspected to the recurrence
of original lung cancer and it was pathologically diagnosed
with percutaneous transthoracic needle biopsy or clinically
diagnosed by combination of brain magnetic resonance im-
aging, bone scintigraphy or fluorodeoxyglucose-positron
emission tomography tests. Local metastasis was defined as
recurrence at the surgical stump or in a lymphatic drainage
area. The 5-year recurrence-free survival was determined as
the interval between surgery for lung cancer and the appear-
ance of recurrence or metastasis. The survival past December
31, 2007, was classified as censored.
Statistical analysis was performed on a Macintosh com-
puter with a Stat View J 4.5 statistical program (Abacus
Concepts Inc., CA). Data are presented as mean  SD (SD).
Differences between two independent samples were tested
using the Mann-Whitney U test. Analysis of categorical data
was performed with Fisher’s exact test probability test. The
probability of 5-year survival was estimated by the method of
Kaplan and Meier. Clinical variables were examined as
possible predictors of survival time using the Cox propor-
tional-hazards model. Hazard ratio and corresponding 95%
CIs were presented. A p value of less than 0.05 was consid-
ered to indicate a statistically significant difference.
RESULTS
Disease Recurrence
The median postoperative period was 28.3 months.
Fifteen patients had postoperative recurrence (seven p-stage
IA cases and eight p-stage IB cases). The median of the time
to recurrence was 12.8 months (range: 6.3–46.0 months) for
the 15 patients who had recurrence. There were seven pa-
tients who had only local metastasis (six cases with medias-
tinal lymph node metastases, one case with recurrence at the
surgical stump), three patients who had both local and distant
metastases (two cases with mediastinal lymph node plus brain
metastasis and one case with recurrence at the surgical stump
plus multiple organ metastasis) and five patients who had
only distant metastases (two cases with bone metastasis, two
cases with brain metastasis, and one case with intrapulmo-
nary metastasis).
Postoperative Levels of Serum CEA
We measured CEA in all 136 patients before surgery
and 2 months after surgery, but not in 11 cases 6 months after
surgery and not in 25 cases 12 months after surgery for the
following reasons; 1 patient died of lung cancer less than 12
months after surgery and the other patients did not visit our
hospital regularly (Figure 1). In the no recurrence group, the
mean levels of serum CEA before surgery significantly de-
creased from 2.0 ng/ml before surgery to 1.4 ng/ml 2 month
after surgery (p  0.0081) and the decrease continued for 12
months. In the recurrence group, there was no difference in
the mean levels at 4 different time points. The mean levels 2
months after surgery were lower in the no recurrence group
than those in the recurrence group (1.4  0.8 ng/ml versus
3.2  2.8 ng/ml, p  0.0057). There was a significant
difference in the chronological change of postoperative CEA
levels between the 2 groups (p 0.0001). Postoperative CEA
levels were defined as the levels measured 2 months after
surgery.
Variables Associated with Recurrence-Free
Survival Time
There was a significant difference between in the re-
currence group (n  15) and in the no recurrence group (n 
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121) in gender, pathologic stage of lung cancer, tumor size
and incidence of vascular invasion or pleural invasion, and
postoperative CEA levels. There was no difference in the
percentage of Eastern Cooperative Oncology Group perfor-
mance status 0 patients and never smokers, preoperative CEA
levels and the type of surgery between the two groups. A total
of 12 p-stage IB patients had adjuvant chemotherapy (8 cases
had UFT therapy and 4 cases had platinum-based doublet
therapy), but there was no difference in the percentage of
patients who had adjuvant chemotherapy between the 2
groups (Table 1). With regard to possible predictors of
recurrence-free survival time by multivariate analysis using
the Cox proportional-hazards model, the risk of postoperative
recurrence increased for patients who had vascular invasion
(hazard ratio: 10.229, 95% CI: 2.811–37.223, p  0.0004).
Postoperative CEA levels also increased the risk of recur-
rence (hazard ratio: 1.650, 95% CI: 1.196–2.275, p 
0.0023) (Table 2).
Receiver operating characteristics curves were con-
structed using the postoperative CEA levels for a predictor of
disease recurrence. The optimal cutoff values were decided as
the specificity of this tumor marker was approximately 80%
or more (Figure 2). Differences in 5-year recurrence-free
survival rate between in patients with high levels of postop-
erative CEA and in patients with low levels of postoperative
CEA were evaluated using different CEA cutoff values (Fig-
ure 3). Setting the cutoff value for postoperative CEA levels
of 2.5 ng/ml, 9 of 16 cases (56%) showed disease recurrence,
while 6 of 120 cases (5%) showed recurrence with the levels
less than or equal to 2.5 ng/ml. There was a significant
difference in 5-year recurrence-free survival rate between the
2 groups (Figure 4). The prediction of postoperative CEA
levels had the sensitivity of 60%, the specificity of 94%, the
positive predictive value (PPV) of 56% and the negative
predictive value (NPV) of 95%.
With regard to the presence of vascular invasion, re-
currence was seen in 11 of 26 cases (42%) with vascular
invasion and in 4 of 110 cases (4%) without vascular inva-
sion. These predictions for disease recurrence presented 67%
sensitivity, 87% specificity, 42% PPV and 96% NPV.
We combined two conditions of postoperative CEA
levels larger than 2.5 ng/ml and the presence of vascular
invasion. In 7 patients who satisfied both these 2 conditions,
5 cases recurred and the prediction had 33% sensitivity, 98%
specificity, 71% PPV and 92% NPV. However, in 101 pa-
tients who did not satisfied either these 2 conditions (patients
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FIGURE 1. Chronological change of postoperative carcino-
embryonic antigen (CEA) levels in p-stage I adenocarcinoma
patients who had disease recurrence and no disease recur-
rence. R (), absence of recurrence; R (), presence of re-
currence. Data are presented as mean  SD (SD). *p  0.05
versus the mean levels of serum CEA before surgery using
the Mann-Whitney U test.
TABLE 1. Univariate Analysis in p-Stage-I Adenocarcinoma
Patients who had Disease Recurrence and who did not have
Disease Recurrence
Characteristic
Recurrence ()
n  15, n (%)
Recurrence ()
n  121, n (%) p
Age: median (range) 72 (49–83) 68 (32–90)
Gender 0.0474
Men 10 (67) 44 (36)
Women 5 (33) 77 (64)
Performance status 0.1964
0 12 (80) 113 (93)
1 3 (20) 8 (7)
Never smokers 6 (40) 83 (69) 0.0563
Preoperative CEA levels
(ng/ml)
5.5  7.6 2.0  2.8 0.1313
Type of surgery 0.1525
Lobectomy 10 (67) 53 (48)
Segmentectomy 5 (33) 69 (56)
Pathological stage 0.0019
IA 7 (47) 102 (84)
IB 8 (53) 19 (16)
Tumor size (mm) 29.3  18.2 19.6  9.8 0.0186
Vascular invasion 11 (73) 15 (12) 0.0001
Pleural invasion (p2 or 3) 4 (27) 2 (2) 0.0002
Postoperative CEA levels
(ng/ml)
3.3  2.8 1.4  0.8 0.0035
Adjuvant UFT therapy: yes 2 (13) 10 (8) 0.8648
CEA, carcinoembryonic antigen; UFT, uracil/tegafur.
TABLE 2. Predictors of Recurrence-Free Survival Time by
Multivariate Analysis Using the Cox Proportional-Hazards
Model
Predictor
Hazard
Ratio
95% confidence
Interval p
Age 0.988 0.923–1.058 0.7253
Gender
Men Reference value
Women 0.463 0.135–1.585 0.1813
Pathological stage
IA Reference value
IB 1.207 0.165–8.798 0.8530
Tumor size 0.992 0.913–1.078 0.8486
Pleural invasion (p2 or 3) 3.307 0.606–18.049 0.1672
Vascular invasion 10.229 2.811–37.223 0.0004
Postoperative CEA levels 1.650 1.196–2.275 0.0023
CEA, carcinoembryonic antigen.
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with both the postoperative CEA levels less than or equal to
2.5 ng/ml and the absence of vascular invasion), there was no
disease recurrence (Table 3).
DISCUSSION
Our results suggest that combined evaluation of post-
operative serum levels of CEA less than or equal to 2.5 ng/ml
and absence of vascular invasion may predict no recurrence
of stage I adenocarcinoma lung cancer.
It has been reported that the prediction of the postopera-
tive CEA levels for disease recurrence are 77% sensitivity, 83%
specificity, 91% PPV and 57% NPV21,22 and that the prediction
of vascular invasion are 49% sensitivity, 77% specificity, 26%
PPV and 90% NPV.4 In the present study, the prediction by
combination of these 2 conditions of postoperative CEA levels
larger than 2.5 ng/ml and the presence of vascular invasion
showed 33% sensitivity, 98% specificity, 71% PPV and 92%
NPV. Although it has been reported that postoperative CEA
levels and vascular invasion are strong predictors for postoper-
ative recurrence in completely resected stage I non-small cell
carcinoma,23–26 it is very difficult to predict beforehand which
p-stage I adenocarcinoma patients has recurrence.
We found that patients who did not satisfy either these two
conditions (patients with both the postoperative CEA levels less
than or equal to 2.5 ng/ml and the absence of vascular invasion)
did not have disease recurrence. Adjuvant chemotherapy has not
been recommended for routine use in p-stage I NSCLC patients
in any country other than Japan.1 Our results suggest that
adjuvant chemotherapy may be needed in adenocarcinoma pa-
tients who satisfied at least one of these two conditions of
postoperative CEA levels larger than 2.5 ng/ml and the presence
of vascular invasion. In our study, 5 of 16 p-stage IB patients
who satisfied at least one of these two conditions had received
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FIGURE 2. Receiver operating characteristics (ROC) curves
were constructed using the postoperative carcinoembryonic
antigen (CEA) levels for a predictor of disease recurrence.
1
0.1
0.01
0.001
0.0001
0
100
1.0
58
2.0
23
3.0
10
4.0
4
5.0
1
P 
va
lu
e
Cut-off values (ng/ml)
Cases with CEA > 
cut-off values (%)
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FIGURE 4. Five-year recurrence survival rates in p-stage I
adenocarcinoma patients with postoperative carcinoembry-
onic antigen (CEA) levels 2.5 ng/ml and in p-stage I ade-
nocarcinoma patients with the levels 2.5 ng/ml.
TABLE 3. Disease Recurrence According to the
Postoperative Serum CEA Levels and Vessel Invasion
Postoperative CEA
Levels (ng/ml)
Vessel
Invasion Total
Recurrence
yes, n (%)
Recurrence
no, n (%)
Stage IA  IB
(n  136)
2.5 Yes 7 5 (71) 2 (29)
2.5 Yes 19 6 (32) 13 (68)
2.5 No 9 4 (44) 5 (56)
2.5 No 101 0 101 (100)
Stage IA (n  109)
2.5 Yes 3 3 (100) 0
2.5 Yes 11 2 (18) 9 (82)
2.5 No 5 2 (20) 3 (60)
2.5 No 90 0 90 (100)
Stage IB (n  27)
2.5 Yes 4 2 (50) 2 (50)
2.5 Yes 8 4 (50) 4 (50)
2.5 No 4 2 (50) 2 (50)
2.5 No 11 0 11 (100)
CEA, carcinoembryonic antigen.
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adjuvant chemotherapy including UFT therapy. Postoperative
recurrence was found in 2 (20%) of 5 cases who had this therapy
and 6 (55%) of 11 case who did not have, although there was not
statistically difference in the recurrence rates because of a small
number of data. It is not clear what type of adjuvant chemother-
apy should be done in those patients.
This study had three limitations. First, there were only
two cases whose preoperative CEA levels were higher than
the reference range. A question arises whether it is worth to
measure postoperative levels for predicting disease recur-
rence in patients with normal values of preoperative CEA. In
this study, the mean levels of serum CEA before surgery
statistically decreased from 2.0 ng/ml to 1.4 ng/ml 2 month
after surgery in patients without recurrence. This result
showed that the decrease of CEA levels after surgery related
to tumor resection even if preoperative levels were within
normal range. Secondly, it is not clear whether or not adju-
vant therapy is beneficial to p-stage I patients when we wait
for 2 months before starting adjuvant therapy. In the present
study, Serum CEA levels were measured a month after
surgery in some cases (unpublished data), but these levels did
not decrease enough to be defined as the postoperative CEA
levels. We think it is useful to first start adjuvant therapy in
cases with vascular invasions identified on the resected spec-
imen and secondly do it in cases with high CEA levels 2
months after surgery. Thirdly the median time to follow-up
after surgery was 28.3 months in this study and it may be
short for evaluating disease recurrence. This reason was that
the number of small-sized adenocarcinoma patients who
received segmentectomy increased for the past several years.
In conclusion, combined evaluation of postoperative CEA
levels and vascular invasion makes it possible to predict disease
recurrence in complete resected p-stage I adenocarcinoma patients.
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